



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

September 11, 2012 6:00 – 8:30 p.m.

PLEASE NOTE NEW START TIMES – PUBLIC SESSION STARTS AT 6:30 PM

- 1. Executive Session** **6:00 - 6:30**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

- 2. Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- 3. DVHA Pharmacy Administration Updates** **6:35 - 6:45**
 - Updates

- 4. Medical Director Update** **6:45 - 6:50**
 - Clinical Programs Update
 - Prescriber Comments

- 5. Follow-up Items from Previous Meetings** **6:50 - 7:00**
 - Atypical Antipsychotics – Pediatric Use

- 6. RetroDUR/DUR** **7:00 – 7:00**
 - None

- 7. Clinical Update: Drug Reviews** **7:00 – 7:15**
(Public comment prior to Board action)
 - Abbreviated New Drug Reviews**
 - Edarbyclor[®] (azilsartan and chlorthalidone) Oral Tablet
 - Oxecta[®] (oxycodone)

 - Full New Drug Reviews**
 - Picato[®] (ingenol mebutate) Topical Gel

- 8. Therapeutic Drug Classes – Periodic Review** **7:15 – 8:10**
(Public comment prior to Board action)
Class review documents available on DVHA web site 9/11/2012 @ 12 Noon
 - Anti-hyperkinesia and Anti-Narcolepsy: ADHD
 - Anticonvulsants-Benzodiazepines
 - Incretin Mimetics (includes new drug review of Bydureon[®])
 - Intranasal Corticosteroids
 - Ophthalmic Prostaglandin Analogues

- 9. New Managed Therapeutic Drug Classes** **8:10 – 8:10**
(Public comment prior to Board action)
- None
- 10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **8:10 – 8:20**
(Public comment prior to Board action)
- Scabicides and Pediculicides
 - Synagis[®] (palivizumab) 2012 Red Book Guideline Update
- 11. General Announcements** **8:20– 8:30**
Selected FDA Safety Alerts
- Ampyra[®] (dalfampridine): Drug Safety Communication - Seizure Risk for Multiple Sclerosis Patients
 - Codeine Use in Certain Children After Tonsillectomy and/or Adenoidectomy: Drug Safety Communication - Risk of Rare, But Life-Threatening Adverse Events or Death
 - Revatio[®] (sildenafil): Drug Safety Communication - Recommendation Against Use in Children
- 12. Adjourn** **8:30**